At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
MK-1006 DFC +1 moredrug
Likely dose
MK-1006 DFC 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Dose Study to Compare the Pharmacokinetics of Two Probe Formulations of MK-1006
In Brief
A Phase 1 clinical trial evaluating MK-1006 DFC and MK-1006 FCT for Type 2 Diabetes. Completed, enrolled 12 participants.
Detailed Summary
This study will assess the pharmacokinetics of two formulations of MK-1006. The primary hypothesis of this study is that the MK-1006 area under the curve (0 to infinity) and maximum concentration after administration of a single 80 mg dose of the dry filled capsule (DFC) and film coated tablet (FCT) formulations of MK-1006 will be similar.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2009
First PostedSep 2009
Primary CompletionNov 2009
Study CompletionDec 2009
TodayJul 2026
First PostedSep 18, 2009
Enrollment StartSep 1, 2009
Primary CompletionNov 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 16.8 years ago
Interventions
MK-1006 DFCdrug
Each dry filled capsule contains 20 mg MK-1006
MK-1006 FCTdrug
Each film coated tablet contains 40 mg of MK-1006